Private company valuation is as much art as science, sometimes as much alchemy as chemistry. Among the few reliable and well-worn guidelines to follow are public companies and recent M&A multiples. This is why we spend so much time refining, tracking and parsing the multiples we use. Oddly, we have observed a strange lag in the re-evaluation of comparable pricing and an over-correction… Read More